A carregar...
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
BACKGROUND: Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation‐predominant irritable bowel syndrome (IBS‐C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS‐C clinical trials, recommending a composite endpoi...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215520/ https://ncbi.nlm.nih.gov/pubmed/27669680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13807 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|